Cocrystal Pharma Inc. (COCP) 1.1500 $COCP
Solid Pipeline and Big Player Backing: Cocrystal Pharma Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Mon Apr 27, 6:00AM CDT
Cocrystal Pharma Inc. (OTCQB: COCP) a Washington-State based pharmaceutical company working to develop antiviral therapeutics as treatments for serious and/or chronic viral diseases, expects to begin clinical studies on several of its antiviral therapeutic treatments in 2015. The company has several drugs in various stages of development for the treatment of Hepatitis C, Influenza, Norovirus, Dengue Fever and others.
InsiderInsights.com Daily Round Up 4/23/15: GE, OMN, COCP, AGCO
InsiderInsights - at Seeking Alpha - Fri Apr 24, 7:53AM CDT
STFC: 22.81 (+0.19), GE: 27.31 (+0.04), OMN: 7.70 (+0.08), AGCO: 50.99 (-0.15), SAM: 263.95 (+1.89), AMGN: 163.44 (+1.08), ILMN: 200.76 (+1.69), NXRT: 14.61 (+0.04), BDCV: 5.11 (-0.04), MPWR: 54.30 (+1.40), WCIC: 23.24 (+0.32), ADS: 300.48 (+3.00), KMX: 73.00 (+0.74), SVVC: 14.90 (-0.01), ALNY: 121.62 (+1.78), GRPN: 6.54 (-0.07), UCTT: 6.17 (+0.02)
Cocrystal Pharma - Overhyped Biotech Or The Next Pharmasset?
Greg Buch - at Seeking Alpha - Tue Apr 07, 10:19AM CDT
Opko and its CEO Dr. Phillip Frost Add MabVax to Their Portfolios
ACCESSWIRE - Mon Apr 06, 6:15PM CDT
CORAL GABLES, FL / ACCESSWIRE / April 6, 2015 / Holding companies invest in the securities of other companies all the time aiming to increase shareholder value. There are hits and there are misses, as with all investments. But Opko Health (NYSE: OPK) has been on such a hot streak in this game especially in the last few months that even relatively small deals deserve attention. Its latest move - both for Opko and for Frost's personal investment trust - is to be part of a $12M private placement into MabVax Therapeutics (OTCQB: MBVX).
OPK: 17.30 (+0.38), PFE: 33.98 (-0.01), JUNO: 40.81 (-2.56), NVCN: 7.32 (+0.56)
InsiderInsights.com Daily Round Up 3/27/15: COCP, GPRO, SJW, AGCO
InsiderInsights - at Seeking Alpha - Sun Mar 29, 12:55PM CDT
GPRO: 51.13 (+1.04), HCOM: 25.45 (+0.06), DPLO: 35.68 (+0.62), AGCO: 50.99 (-0.15), ENV: 44.20 (+0.11), LPI: 14.31 (+0.47), GOOG: 532.30 (-1.55), NOW: 77.26 (+1.55), ARMK: 31.70 (+0.11), JAZZ: 180.06 (+2.05), GLF: 14.50 (-0.29), SJW: 30.06 (+0.30), JGW: 9.50 (-0.08), ALCO: 49.29 (-0.12), FI: 20.98 (+0.07), CRM: 72.80 (+0.40)
Opko's Frost Inks Levon Deal with Israel's SciVac, a Hint for the Next Merger?
ACCESSWIRE - Fri Mar 20, 10:30AM CDT
NEW YORK, NY / ACCESSWIRE / March 20, 2015 / On September 11 last year, a little-known Israeli financial magazine called Globes came out with a report that Dr. Phillip Frost, Chairman and CEO of Opko Health (NYSE:OPK), and then Chairman of Teva Pharmaceuticals (NYSE:TEVA), was interested in moving a private Israeli biotech called SciVac, 45% owned by Opko, into a corporate shell and making it public.
OPK: 17.30 (+0.38), TEVA: 60.19 (-0.04)
Cocrystal Pharma announces changes in executive positions
M2 - Fri Mar 13, 7:15AM CDT
Pharmaceutical company Cocrystal Pharma (OTCQB:COCP) reported on Thursday that Dr Gary Wilcox will step down as its chief executive officer due to medical reasons.
Cocrystal Pharma to Appoint Jeffrey Meckler as Interim Chief Executive Officer
Marketwired - Thu Mar 12, 6:30AM CDT
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today that due to medical reasons, Dr. Gary Wilcox will step down as the current Chief Executive Officer. Mr. Jeffrey Meckler has been appointed as the Interim Chief Executive Officer of the Company effective with the filing of the Form 10-K, later this month. Dr. Wilcox will become the Vice Chairman of the Board of Directors and continue as a senior advisor to the company. Mr. Meckler will continue as a Director of the Company, and Dr. Raymond F. Schinazi will become the Chairman of the Board.
QLTI: 3.78 (+0.06), OPK: 17.30 (+0.38), PFE: 33.98 (-0.01)
Cocrystal Pharma to Present at Barclays Global Healthcare Conference on Thursday, March 12
Marketwired - Tue Mar 03, 8:24AM CST
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today that it will present at the Barclays 2015 Global Healthcare Conference on Thursday, March 12, 2015 at 8:00 AM ET at Loews Miami Beach Hotel in Miami, Florida. Dr. Raymond F. Schinazi, co-chairman of the Board of Directors of Cocrystal Pharma, will be presenting on behalf of the Company.
OPK: 17.30 (+0.38)
Nasopharyngitis (Common Cold) - Pipeline Review, H1 2015 - 11 Drug Profiles from 4 Companies
M2 - Mon Mar 02, 8:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/29q354/nasopharyngitis) has announced the addition of the "Nasopharyngitis (Common Cold) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Nasopharyngitis (Common Cold), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngitis (Common Cold) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cocrystal Pharma, Inc. - Neos Therapeutics, Inc. - Orbis Biosciences, Inc. - Vernalis plc Drug Profiles - (chlorpheniramine codeine) - Antibody to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - CCP-01 - CCP-05 - CCP-06 - CCP-07 - CCP-08 - guaifenesin ER - Small Molecule for Cough and Cold - Small Molecule to Inhibit MAPK13 for Asthma and Cold - Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold For more information visit http://www.researchandmarkets.com/research/29...haryngitis
Patience Pays Off for Opko and Cocrystal Investors, Will It Also for Pershing Gold?
ACCESSWIRE - Wed Feb 11, 8:26AM CST
NEW YORK, NY / ACCESSWIRE / February 11, 2015 / Teva (NYSE:TEVA) has a new chairman. As of February 5 and after four and a half years at the helm of the largest generics manufacturer in the world, Dr. Phillip Frost has resigned his position. This was announced back in June and is no surprise, and wouldn't be all that noteworthy if not for the fact that other companies that Dr. Frost is heavily involved and invested in are suddenly making rather large upside moves.
GILD: 111.00 (+1.70), OPK: 17.30 (+0.38), TEVA: 60.19 (-0.04)
The Golden Long: Frost's Pershing Gold Poised For A Significant Upside Move
Wall Street Advisors - Seeking Alpha - Wed Feb 11, 3:28AM CST
Gold is off to a strong start in 2015. Gold priced in USD has performed well, up about 6% so far year to date. With the recent strength of the U.S. dollar, though, it is surprising for gold to also look so strong as they typically move at an inverse....
OPK: 17.30 (+0.38), MDW: 0.09 (-0.01)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 32.83 (+1.99), JNJ: 103.42 (+1.12), UTHR: 179.30 (+6.55), MRK: 60.01 (-0.22), NNVC: 1.66 (unch), GSK: 44.66 (-0.11), SIGA: 2.05 (-0.21)
Biotechs to Follow in 2015 off Fresh Insider Moves
ACCESSWIRE - Tue Jan 06, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2015 / Insider moves are always interesting to equity traders no matter where they occur, but more than any other sector, insider buys tend to inspire the most chatter around biotech. This is mostly due to the esoteric science and trial statistics that often determine the fate of a firm, which company and other biotech insiders tend to know more about than even premium hedge fund operators.
ADXS: 20.90 (+0.82), SGEN: 40.50 (+0.56), GILD: 111.00 (+1.70), OPK: 17.30 (+0.38), MRK: 60.01 (-0.22), IBB: 360.30 (+4.69), AGIO: 115.94 (+3.16), TEVA: 60.19 (-0.04), CELG: 116.37 (+0.84)
Cocrystal Pharma: Small Cap Company With Transformative Merger
Leonard Yaffe - at Seeking Alpha - Thu Nov 27, 12:51PM CST
Cocrystal and RFS complete marriage
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 11:59AM CST
Cocrystal Pharma and RFS Pharma Merge to Create Advanced Antiviral Development Organization
Marketwired - Tue Nov 25, 8:52AM CST
Cocrystal Pharma, Inc. (OTCQB: COCP), a biotechnology company developing novel antiviral therapeutics for human diseases, today announced the closing of its merger with RFS Pharma, LLC, a privately owned biotech company founded by renowned drug developer, Dr. Raymond Schinazi. Since 2004, RFS Pharma has been working on the development of innovative drugs to treat human viral diseases.
OPK: 17.30 (+0.38)
Cocrystal Pharma Reports Third Quarter Financial Results and Select Program Updates
Marketwired - Fri Nov 14, 8:15AM CST
Cocrystal Pharma, Inc. (the "Company"
(OTCQB: COCP), a biotechnology company focused on developing new antiviral therapeutics for human diseases, today reported financial results for the third quarter ended September 30, 2014.
Solid Pipeline and Big Player Backing: Cocrystal Pharma Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Mon Apr 27, 6:00AM CDT
Cocrystal Pharma Inc. (OTCQB: COCP) a Washington-State based pharmaceutical company working to develop antiviral therapeutics as treatments for serious and/or chronic viral diseases, expects to begin clinical studies on several of its antiviral therapeutic treatments in 2015. The company has several drugs in various stages of development for the treatment of Hepatitis C, Influenza, Norovirus, Dengue Fever and others.
InsiderInsights.com Daily Round Up 4/23/15: GE, OMN, COCP, AGCO
InsiderInsights - at Seeking Alpha - Fri Apr 24, 7:53AM CDT
STFC: 22.81 (+0.19), GE: 27.31 (+0.04), OMN: 7.70 (+0.08), AGCO: 50.99 (-0.15), SAM: 263.95 (+1.89), AMGN: 163.44 (+1.08), ILMN: 200.76 (+1.69), NXRT: 14.61 (+0.04), BDCV: 5.11 (-0.04), MPWR: 54.30 (+1.40), WCIC: 23.24 (+0.32), ADS: 300.48 (+3.00), KMX: 73.00 (+0.74), SVVC: 14.90 (-0.01), ALNY: 121.62 (+1.78), GRPN: 6.54 (-0.07), UCTT: 6.17 (+0.02)
Cocrystal Pharma - Overhyped Biotech Or The Next Pharmasset?
Greg Buch - at Seeking Alpha - Tue Apr 07, 10:19AM CDT
Opko and its CEO Dr. Phillip Frost Add MabVax to Their Portfolios
ACCESSWIRE - Mon Apr 06, 6:15PM CDT
CORAL GABLES, FL / ACCESSWIRE / April 6, 2015 / Holding companies invest in the securities of other companies all the time aiming to increase shareholder value. There are hits and there are misses, as with all investments. But Opko Health (NYSE: OPK) has been on such a hot streak in this game especially in the last few months that even relatively small deals deserve attention. Its latest move - both for Opko and for Frost's personal investment trust - is to be part of a $12M private placement into MabVax Therapeutics (OTCQB: MBVX).
OPK: 17.30 (+0.38), PFE: 33.98 (-0.01), JUNO: 40.81 (-2.56), NVCN: 7.32 (+0.56)
InsiderInsights.com Daily Round Up 3/27/15: COCP, GPRO, SJW, AGCO
InsiderInsights - at Seeking Alpha - Sun Mar 29, 12:55PM CDT
GPRO: 51.13 (+1.04), HCOM: 25.45 (+0.06), DPLO: 35.68 (+0.62), AGCO: 50.99 (-0.15), ENV: 44.20 (+0.11), LPI: 14.31 (+0.47), GOOG: 532.30 (-1.55), NOW: 77.26 (+1.55), ARMK: 31.70 (+0.11), JAZZ: 180.06 (+2.05), GLF: 14.50 (-0.29), SJW: 30.06 (+0.30), JGW: 9.50 (-0.08), ALCO: 49.29 (-0.12), FI: 20.98 (+0.07), CRM: 72.80 (+0.40)
Opko's Frost Inks Levon Deal with Israel's SciVac, a Hint for the Next Merger?
ACCESSWIRE - Fri Mar 20, 10:30AM CDT
NEW YORK, NY / ACCESSWIRE / March 20, 2015 / On September 11 last year, a little-known Israeli financial magazine called Globes came out with a report that Dr. Phillip Frost, Chairman and CEO of Opko Health (NYSE:OPK), and then Chairman of Teva Pharmaceuticals (NYSE:TEVA), was interested in moving a private Israeli biotech called SciVac, 45% owned by Opko, into a corporate shell and making it public.
OPK: 17.30 (+0.38), TEVA: 60.19 (-0.04)
Cocrystal Pharma announces changes in executive positions
M2 - Fri Mar 13, 7:15AM CDT
Pharmaceutical company Cocrystal Pharma (OTCQB:COCP) reported on Thursday that Dr Gary Wilcox will step down as its chief executive officer due to medical reasons.
Cocrystal Pharma to Appoint Jeffrey Meckler as Interim Chief Executive Officer
Marketwired - Thu Mar 12, 6:30AM CDT
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today that due to medical reasons, Dr. Gary Wilcox will step down as the current Chief Executive Officer. Mr. Jeffrey Meckler has been appointed as the Interim Chief Executive Officer of the Company effective with the filing of the Form 10-K, later this month. Dr. Wilcox will become the Vice Chairman of the Board of Directors and continue as a senior advisor to the company. Mr. Meckler will continue as a Director of the Company, and Dr. Raymond F. Schinazi will become the Chairman of the Board.
QLTI: 3.78 (+0.06), OPK: 17.30 (+0.38), PFE: 33.98 (-0.01)
Cocrystal Pharma to Present at Barclays Global Healthcare Conference on Thursday, March 12
Marketwired - Tue Mar 03, 8:24AM CST
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today that it will present at the Barclays 2015 Global Healthcare Conference on Thursday, March 12, 2015 at 8:00 AM ET at Loews Miami Beach Hotel in Miami, Florida. Dr. Raymond F. Schinazi, co-chairman of the Board of Directors of Cocrystal Pharma, will be presenting on behalf of the Company.
OPK: 17.30 (+0.38)
Nasopharyngitis (Common Cold) - Pipeline Review, H1 2015 - 11 Drug Profiles from 4 Companies
M2 - Mon Mar 02, 8:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/29q354/nasopharyngitis) has announced the addition of the "Nasopharyngitis (Common Cold) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Nasopharyngitis (Common Cold), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngitis (Common Cold) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cocrystal Pharma, Inc. - Neos Therapeutics, Inc. - Orbis Biosciences, Inc. - Vernalis plc Drug Profiles - (chlorpheniramine codeine) - Antibody to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - CCP-01 - CCP-05 - CCP-06 - CCP-07 - CCP-08 - guaifenesin ER - Small Molecule for Cough and Cold - Small Molecule to Inhibit MAPK13 for Asthma and Cold - Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold For more information visit http://www.researchandmarkets.com/research/29...haryngitis
Patience Pays Off for Opko and Cocrystal Investors, Will It Also for Pershing Gold?
ACCESSWIRE - Wed Feb 11, 8:26AM CST
NEW YORK, NY / ACCESSWIRE / February 11, 2015 / Teva (NYSE:TEVA) has a new chairman. As of February 5 and after four and a half years at the helm of the largest generics manufacturer in the world, Dr. Phillip Frost has resigned his position. This was announced back in June and is no surprise, and wouldn't be all that noteworthy if not for the fact that other companies that Dr. Frost is heavily involved and invested in are suddenly making rather large upside moves.
GILD: 111.00 (+1.70), OPK: 17.30 (+0.38), TEVA: 60.19 (-0.04)
The Golden Long: Frost's Pershing Gold Poised For A Significant Upside Move
Wall Street Advisors - Seeking Alpha - Wed Feb 11, 3:28AM CST
Gold is off to a strong start in 2015. Gold priced in USD has performed well, up about 6% so far year to date. With the recent strength of the U.S. dollar, though, it is surprising for gold to also look so strong as they typically move at an inverse....
OPK: 17.30 (+0.38), MDW: 0.09 (-0.01)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 32.83 (+1.99), JNJ: 103.42 (+1.12), UTHR: 179.30 (+6.55), MRK: 60.01 (-0.22), NNVC: 1.66 (unch), GSK: 44.66 (-0.11), SIGA: 2.05 (-0.21)
Biotechs to Follow in 2015 off Fresh Insider Moves
ACCESSWIRE - Tue Jan 06, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2015 / Insider moves are always interesting to equity traders no matter where they occur, but more than any other sector, insider buys tend to inspire the most chatter around biotech. This is mostly due to the esoteric science and trial statistics that often determine the fate of a firm, which company and other biotech insiders tend to know more about than even premium hedge fund operators.
ADXS: 20.90 (+0.82), SGEN: 40.50 (+0.56), GILD: 111.00 (+1.70), OPK: 17.30 (+0.38), MRK: 60.01 (-0.22), IBB: 360.30 (+4.69), AGIO: 115.94 (+3.16), TEVA: 60.19 (-0.04), CELG: 116.37 (+0.84)
Cocrystal Pharma: Small Cap Company With Transformative Merger
Leonard Yaffe - at Seeking Alpha - Thu Nov 27, 12:51PM CST
Cocrystal and RFS complete marriage
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 11:59AM CST
Cocrystal Pharma and RFS Pharma Merge to Create Advanced Antiviral Development Organization
Marketwired - Tue Nov 25, 8:52AM CST
Cocrystal Pharma, Inc. (OTCQB: COCP), a biotechnology company developing novel antiviral therapeutics for human diseases, today announced the closing of its merger with RFS Pharma, LLC, a privately owned biotech company founded by renowned drug developer, Dr. Raymond Schinazi. Since 2004, RFS Pharma has been working on the development of innovative drugs to treat human viral diseases.
OPK: 17.30 (+0.38)
Cocrystal Pharma Reports Third Quarter Financial Results and Select Program Updates
Marketwired - Fri Nov 14, 8:15AM CST
Cocrystal Pharma, Inc. (the "Company"
(OTCQB: COCP), a biotechnology company focused on developing new antiviral therapeutics for human diseases, today reported financial results for the third quarter ended September 30, 2014. 
